CARLSBAD, Calif., Oct. 20 /PRNewswire/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced that it ranked number 41 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the five year period from 2005–2009. Genoptix grew 3,451 percent during this period.
Tina S. Nova, Ph.D., President and CEO of Genoptix, credits their specialized, physician-directed approach to testing and diagnosis with the company's revenue growth. "We are honored to rank among the top 50 fastest-growing technology companies in North America for the third year in a row based on our performance from 2005 to 2009," said Dr. Nova. "We have grown by focusing on the needs of community-based hematologists and oncologists and by adapting to a continually changing environment, and this recognition is a testament to the exceptional execution of the entire Genoptix team."
"Genoptix, Inc. and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader. "Deloitte commends Genoptix for this impressive accomplishment."
In addition, Genoptix was ranked the second fastest-growing company in the San Diego region, according to the Technology Fast 500. Overall, Technology Fast 500™ award winners for 2010 had revenue growth ranging from 146 percent to 164,079 percent from 2005 to 2009, with an average growth of 2,361 percent.
"Genoptix has proved itself to be one of the fastest growing companies in North America, and we are proud to honor them as one of the 2010 Technology Fast 500™," said Mark Jensen, managing partner, venture capital services, Deloitte & Touche LLP.
About Genoptix, Inc.
Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.
As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the Company’s business that are not historical facts may be considered “forward-looking statements,” including statements regarding the value of the Company’s services, the Company’s ability to focus on the needs of community-based hematologists and oncologists, to provide high quality diagnostic services and to address and adapt to the changing environment, the success of the Company’s business model, the Company’s ability to optimize the care of patients, and the Company’s growth prospects. Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause the Company’s results to differ materially and adversely from the statements contained herein. These risks and uncertainties are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009 and most recent Quarterly Report on Form 10-Q and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
|SOURCE Genoptix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved